These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 33780423)

  • 1. Short-term Tolerance of Nasally-administered NeuroEPO in Patients with Parkinson Disease.
    García-Llano M; Pedroso-Ibáñez I; Morales-Chacón L; Rodríguez-Obaya T; Pérez-Ruiz L; Sosa-Testé I; Amaro-González D; Bringas-Vega ML
    MEDICC Rev; 2021 Jan; 23(1):49-54. PubMed ID: 33780423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nasal administration of the neuroprotective candidate NeuroEPO to healthy volunteers: a randomized, parallel, open-label safety study.
    Santos-Morales O; Díaz-Machado A; Jiménez-Rodríguez D; Pomares-Iturralde Y; Festary-Casanovas T; González-Delgado CA; Pérez-Rodríguez S; Alfonso-Muñoz E; Viada-González C; Piedra-Sierra P; García-García I; Amaro-González D; ; García-Rodríguez JC; Sosa-Testé I; Lagarto-Parra A; Barrero-Viera L; David-Baldo M; Tamayo-Rodríguez M; Rivero-Vázquez I; González-Gamiz G; Martín-Trujillo A; Rodríguez-Fernández Y; Ledo-de la Luz AA; Álvarez-Delgado M; Howland-Álvarez I; Cruz-Gómez Y
    BMC Neurol; 2017 Jul; 17(1):129. PubMed ID: 28676085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of Cuban recombinant human erythropoietin in Parkinson's disease treatment.
    Pedroso I; Bringas ML; Aguiar A; Morales L; Alvarez M; Valdés PA; Alvarez L
    MEDICC Rev; 2012 Jan; 14(1):11-7. PubMed ID: 22334107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erythropoietin in Spinocerebellar Ataxia Type 2: Feasibility and Proof-of-Principle Issues from a Randomized Controlled Study.
    Rodriguez-Labrada R; Ortega-Sanchez R; Hernández Casaña P; Santos Morales O; Padrón-Estupiñan MDC; Batista-Nuñez M; Jiménez Rodríguez D; Canales-Ochoa N; Peña Acosta A; Medrano Montero J; Labrada Aguilera PE; Estupiñán Rodriguez A; Vazquez-Mojena Y; Almaguer Gotay D; Aymed-García J; García-García I; Torres Vega R; Viada González C; Valenzuela Silva CM; Silva Ricardo Y; Columbié Ximelis J; Tribin Rivero K; Valle Cabrera R; García-Rodriguez JC; Crombet Ramos T; Amaro-González D; Rodriguez-Obaya T; Velázquez-Pérez L
    Mov Disord; 2022 Jul; 37(7):1516-1525. PubMed ID: 35607776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protective Activity of Erythropoyetine in the Cognition of Patients with Parkinson's Disease.
    Pedroso I; Garcia M; Casabona E; Morales L; Bringas ML; Pérez L; Rodríguez T; Sosa I; Ricardo Y; Padrón A; Amaro D
    Behav Sci (Basel); 2018 May; 8(5):51. PubMed ID: 29862060
    [No Abstract]   [Full Text] [Related]  

  • 6. The Effect of Neuroepo on Cognition in Parkinson's Disease Patients Is Mediated by Electroencephalogram Source Activity.
    Bringas Vega ML; Pedroso Ibáñez I; Razzaq FA; Zhang M; Morales Chacón L; Ren P; Galan Garcia L; Gan P; Virues Alba T; Lopez Naranjo C; Jahanshahi M; Bosch-Bayard J; Valdes-Sosa PA
    Front Neurosci; 2022; 16():841428. PubMed ID: 35844232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant human erythropoietin in the treatment of acute ischemic stroke.
    Ehrenreich H; Weissenborn K; Prange H; Schneider D; Weimar C; Wartenberg K; Schellinger PD; Bohn M; Becker H; Wegrzyn M; Jähnig P; Herrmann M; Knauth M; Bähr M; Heide W; Wagner A; Schwab S; Reichmann H; Schwendemann G; Dengler R; Kastrup A; Bartels C;
    Stroke; 2009 Dec; 40(12):e647-56. PubMed ID: 19834012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of iorEPOCIM for chemotherapy- or radiotherapy-induced anemia in pediatric cancer patients.
    Vargas A; Mendoza I; Uranga R; González A; Martínez L; Caballero I; Piedra P; Saurez G; Verdecia M; Cabanas R
    MEDICC Rev; 2010 Jul; 12(3):27-31. PubMed ID: 20697335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NeuroEPO Preserves Neurons from Glutamate-Induced Excitotoxicity.
    Garzón F; Coimbra D; Parcerisas A; Rodriguez Y; García JC; Soriano E; Rama R
    J Alzheimers Dis; 2018; 65(4):1469-1483. PubMed ID: 30175978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroprotective Effects of neuroEPO Using an In Vitro Model of Stroke.
    Fernando G; Yamila R; Cesar GJ; Ramón R
    Behav Sci (Basel); 2018 Feb; 8(2):. PubMed ID: 29438293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intranasal erythropoietin therapy in nervous system disorders.
    Genc S; Zadeoglulari Z; Oner MG; Genc K; Digicaylioglu M
    Expert Opin Drug Deliv; 2011 Jan; 8(1):19-32. PubMed ID: 21143002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The nasal route as a potential pathway for delivery of erythropoietin in the treatment of acute ischemic stroke in humans.
    Garcia-Rodriguez JC; Sosa-Teste I
    ScientificWorldJournal; 2009 Sep; 9():970-81. PubMed ID: 19768354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intranasal formulation of erythropoietin (EPO) showed potent protective activity against amyloid toxicity in the Aβ₂₅₋₃₅ non-transgenic mouse model of Alzheimer's disease.
    Maurice T; Mustafa MH; Desrumaux C; Keller E; Naert G; de la C García-Barceló M; Rodríguez Cruz Y; Garcia Rodríguez JC
    J Psychopharmacol; 2013 Nov; 27(11):1044-57. PubMed ID: 23813967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erythropoietin and subarachnoid hemorrhage.
    Grasso G; Sfacteria A
    J Neurosurg; 2010 Mar; 112(3):699-700. PubMed ID: 20192676
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of two recombinant erythropoietin formulations in patients with anemia due to end-stage renal disease on hemodialysis: a parallel, randomized, double blind study.
    Pérez-Oliva JF; Casanova-González M; García-García I; Porrero-Martín PJ; Valenzuela-Silva CM; Hernández-Montero T; Lagarde-Ampudia M; Casanova-Kutsareva Y; Avila-Albuerne Y; Vargas-Batista A; Bobillo-López H; Herrera-Valdés R; López-Saura PA;
    BMC Nephrol; 2005 May; 6():5. PubMed ID: 15910687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absence of hematological side effects in acute and subacute nasal dosing of erythropoietin with a low content of sialic acid.
    Lagarto A; Bueno V; Guerra I; Valdés O; Couret M; López R; Vega Y
    Exp Toxicol Pathol; 2011 Sep; 63(6):563-7. PubMed ID: 20488687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant human erythropoietin for treating treatment-resistant depression: a double-blind, randomized, placebo-controlled phase 2 trial.
    Miskowiak KW; Vinberg M; Christensen EM; Bukh JD; Harmer CJ; Ehrenreich H; Kessing LV
    Neuropsychopharmacology; 2014 May; 39(6):1399-408. PubMed ID: 24322509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nasal neuro EPO could be a reliable choice for neuroprotective stroke treatment.
    Parra AL; Rodriguez JC
    Cent Nerv Syst Agents Med Chem; 2012 Mar; 12(1):60-8. PubMed ID: 22376076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial.
    LeWitt PA; Hauser RA; Pahwa R; Isaacson SH; Fernandez HH; Lew M; Saint-Hilaire M; Pourcher E; Lopez-Manzanares L; Waters C; Rudzínska M; Sedkov A; Batycky R; Oh C;
    Lancet Neurol; 2019 Feb; 18(2):145-154. PubMed ID: 30663606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and preliminary efficacy of intranasal insulin for cognitive impairment in Parkinson disease and multiple system atrophy: A double-blinded placebo-controlled pilot study.
    Novak P; Pimentel Maldonado DA; Novak V
    PLoS One; 2019; 14(4):e0214364. PubMed ID: 31022213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.